JP2011516610A5 - - Google Patents

Download PDF

Info

Publication number
JP2011516610A5
JP2011516610A5 JP2011505149A JP2011505149A JP2011516610A5 JP 2011516610 A5 JP2011516610 A5 JP 2011516610A5 JP 2011505149 A JP2011505149 A JP 2011505149A JP 2011505149 A JP2011505149 A JP 2011505149A JP 2011516610 A5 JP2011516610 A5 JP 2011516610A5
Authority
JP
Japan
Prior art keywords
optionally substituted
alkyl
compound
group
optionally
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011505149A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011516610A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/040567 external-priority patent/WO2009134616A2/en
Publication of JP2011516610A publication Critical patent/JP2011516610A/ja
Publication of JP2011516610A5 publication Critical patent/JP2011516610A5/ja
Pending legal-status Critical Current

Links

JP2011505149A 2008-04-15 2009-04-14 Ｃ型肝炎ウイルス複製の新規な阻害剤 Pending JP2011516610A (ja)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US4521408P 2008-04-15 2008-04-15
US4521908P 2008-04-15 2008-04-15
US61/045,219 2008-04-15
US61/045,214 2008-04-15
US10985608P 2008-10-30 2008-10-30
US61/109,856 2008-10-30
US11791608P 2008-11-25 2008-11-25
US61/117,916 2008-11-25
US14833709P 2009-01-29 2009-01-29
US61/148,337 2009-01-29
PCT/US2009/040567 WO2009134616A2 (en) 2008-04-15 2009-04-14 Novel inhibitors of hepatitis c virus replication

Publications (2)

Publication Number Publication Date
JP2011516610A JP2011516610A (ja) 2011-05-26
JP2011516610A5 true JP2011516610A5 (enExample) 2012-06-07

Family

ID=41078055

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011505149A Pending JP2011516610A (ja) 2008-04-15 2009-04-14 Ｃ型肝炎ウイルス複製の新規な阻害剤

Country Status (10)

Country Link
US (1) US20090257979A1 (enExample)
EP (1) EP2283002A2 (enExample)
JP (1) JP2011516610A (enExample)
KR (1) KR20110004439A (enExample)
CN (1) CN102026990A (enExample)
AU (1) AU2009241514A1 (enExample)
BR (1) BRPI0911259A2 (enExample)
CA (1) CA2720846A1 (enExample)
MX (1) MX2010011307A (enExample)
WO (1) WO2009134616A2 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2056675T1 (sl) 2006-10-12 2019-08-30 Galera Labs, Llc Postopki za zdravljenje oralnega mukozitisa
WO2011049988A2 (en) * 2009-10-20 2011-04-28 Eiger Biopharmaceuticals, Inc. Indazoles to treat flaviviridae virus infection
TW201121968A (en) * 2009-11-09 2011-07-01 Intermune Inc Novel inhibitors of hepatitis C virus replication
CA3120505C (en) * 2011-09-26 2024-11-12 Galera Labs, Llc METHODS OF TREATING DISEASES
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
SE1450131A1 (sv) 2011-10-21 2014-05-07 Abbvie Inc DAA-kombinationsbehandling (t.ex. med ABT-072 eller ABT-333)för användning vid behandling av HCV
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
SE1450130A1 (sv) 2011-10-21 2014-05-07 Abbvie Inc Förfaranden för att behandla hcv innefattande minst två direktverkande antivirala agenser, ribavirin men inte interferon
WO2015018797A2 (en) * 2013-08-05 2015-02-12 Haplogen Gmbh Antiviral compounds
CN105991908B (zh) * 2015-03-16 2019-06-07 迈科威特株式会社 摄像机模块用滤光器转换装置及包含该模块的移动设备
EP3738967A1 (en) 2015-08-11 2020-11-18 Galera Labs, LLC Pentaaza macrocyclic ring complexes possessing oral bioavailability
CN109689063A (zh) 2016-04-28 2019-04-26 埃默里大学 含有炔烃的核苷酸和核苷治疗组合物及其相关用途
EP3452060A4 (en) 2016-05-03 2020-01-01 Galera Labs, LLC Combination therapy for cancer treatment
CN109906081A (zh) 2016-09-01 2019-06-18 加莱拉实验室有限责任公司 利用五氮杂大环络合物和抗坏血酸类化合物的联合癌症疗法
EA201992431A1 (ru) 2017-10-13 2020-03-13 ГАЛЕРА ЛЭБЗ, ЭлЭлСи Комбинированная иммунотерапия рака с использованием пента-аза-макроциклического кольцевого комплекса

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6025984A (ja) * 1983-07-22 1985-02-08 Tokyo Inst Of Technol ベンゾチアジアジン誘導体の製造方法
JPH0216448A (ja) * 1988-07-04 1990-01-19 Fuji Photo Film Co Ltd 化学物質の分配係数の推算処理方法
CZ220498A3 (cs) * 1996-01-17 1998-11-11 Novo Nordisk A/S Deriváty 1,2,4-thiadiazinu a 1,4-thiazinu, příprava a použití
US6242443B1 (en) * 1996-06-21 2001-06-05 Novo Nordisk Ais 1,2,4-benzothiadiazine derivatives, their preparation and use
US6156700A (en) * 1997-09-17 2000-12-05 American Cyanmid Company 3-(1,2-Benzisothiazol- and isoxazol-5-yl)-2,4(1H,3H)-pyrimidinedione or thione and 3-(1,2-benzisothiazol- and isoxazol-5-yl)-4(3H)-pyrimidinone or thione herbicidal agents
US6943159B1 (en) * 1998-02-18 2005-09-13 Neurosearch A/S Compounds and their use as positive AMPA receptor modulators
US7902203B2 (en) * 2002-11-01 2011-03-08 Abbott Laboratories, Inc. Anti-infective agents
US20040162285A1 (en) * 2002-11-01 2004-08-19 Pratt John K. Anti-infective agents
ATE493408T1 (de) * 2002-11-01 2011-01-15 Abbott Lab Antiinfektiöse mittel
US20040097492A1 (en) * 2002-11-01 2004-05-20 Pratt John K Anti-infective agents
US20050075331A1 (en) * 2003-10-06 2005-04-07 Pratt John K. Anti-infective agents
JP4887139B2 (ja) * 2003-03-25 2012-02-29 武田薬品工業株式会社 ジペプチジルペプチダーゼインヒビター
US7378414B2 (en) * 2003-08-25 2008-05-27 Abbott Laboratories Anti-infective agents
RU2007110531A (ru) * 2004-08-23 2008-09-27 Ф.Хоффманн-Ля Рош Аг (Ch) Гетероциклические противовирусные соединения
US8093273B2 (en) * 2004-10-20 2012-01-10 Resverlogix Corp. Flavanoids and isoflavanoids for the prevention and treatment of cardiovascular diseases
WO2006093801A1 (en) * 2005-02-25 2006-09-08 Abbott Laboratories Thiadiazine derivatives useful as anti-infective agents
CN101189230A (zh) * 2005-05-04 2008-05-28 弗·哈夫曼-拉罗切有限公司 抗病毒的杂环化合物
KR101384266B1 (ko) * 2006-06-22 2014-04-24 애나디스 파마슈티칼스, 인코포레이티드 파이로［1,2-ｂ］파이리다지논 화합물
JP4199273B2 (ja) * 2006-08-29 2008-12-17 本田技研工業株式会社 車両状態推定装置
CL2007003587A1 (es) * 2006-12-12 2008-07-04 Anadys Pharmaceuticals Inc Compuestos derivados de pirimidinas sustituidas; composicion farmaceutica que comprende a dichos compuestos y otro agente activo; y su uso para tratar o prevenir la infeccion de la hepatitis c.
US20080188466A1 (en) * 2006-12-21 2008-08-07 Anadys Pharmaceuticals, Inc. Pyridazinone compounds
KR101444489B1 (ko) * 2007-02-01 2014-09-24 리스버로직스 코퍼레이션 심혈관 질환을 예방 및 치료하기 위한 화합물
US20080227774A1 (en) * 2007-03-15 2008-09-18 Frank Ruebsam 5,5-disubstituted-indolizinone compounds
US7834009B2 (en) * 2007-08-27 2010-11-16 Anadys Pharmaceuticals, Inc. 4-hydroxy-5,6-dihydro-1H-pyridin-2-one compounds
TWI438206B (zh) * 2008-06-10 2014-05-21 Anadys Pharmaceuticals Inc 〔１，２，４〕噻二１，１二氧化物化合物

Similar Documents

Publication Publication Date Title
JP2011516610A5 (enExample)
JP2011219498A5 (enExample)
JP2013523765A5 (enExample)
JP2013503846A5 (enExample)
EA200901241A1 (ru) Соединения для лечения гепатита с
EA201290053A1 (ru) Ингибиторы вирусов flaviviridae
JP2010524932A5 (enExample)
EA201491179A1 (ru) 2',4'-дифтор-2'-метил замещенные нуклеозидные производные в качестве ингибиторов репликации рнк вируса гепатита с
NO20082934L (no) Antivirale nukleotider
JP2016506960A5 (enExample)
JP2012041349A5 (enExample)
JP2014500861A5 (enExample)
JP2013537203A5 (enExample)
WO2008085508A3 (en) Nucleoside aryl phosphoramidates for the treatment of rna-dependent rna viral infection
JP2017515901A5 (enExample)
JP2012519691A5 (enExample)
JP2014500265A5 (enExample)
EA025252B1 (ru) Способы и соединения для лечения вирусных инфекций paramyxoviridae
TR201815272T4 (tr) İnfluenza virüs replikasyonu inhibitörleri.
JP2014503516A5 (enExample)
JP2011520906A5 (enExample)
WO2007095269A3 (en) Nucleoside aryl phosphoramidates for the treatment of rna-dependent rna viral infection
NZ593712A (en) Intermediates for synthesising nucleoside aryl phosphoramidates
EA200802346A1 (ru) Циклопропилконденсированные индолобензазепиновые ингибиторы белка ns5b вируса гепатита с
MX2010002904A (es) N-fenil-dioxo-hidropirimidinas utiles como inhibidores de virus de hepatitis c (hcv).